{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:11:17Z","timestamp":1790611877498,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017202","name":"Fundaci\u00f3n de Investigaci\u00f3n HM Hospitales","doi-asserted-by":"publisher","award":["MAPFRE 2024"],"award-info":[{"award-number":["MAPFRE 2024"]}],"id":[{"id":"10.13039\/100017202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"CIBER","doi-asserted-by":"publisher","award":["CB06\/05\/1131"],"award-info":[{"award-number":["CB06\/05\/1131"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003350","name":"Fundaci\u00f3n Mapfre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/01037"],"award-info":[{"award-number":["PI23\/01037"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR20\/00033"],"award-info":[{"award-number":["JR20\/00033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD24\/0014\/0009"],"award-info":[{"award-number":["RD24\/0014\/0009"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106674","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T23:35:48Z","timestamp":1754955348000},"page":"106674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A systematic review and meta-analysis of real-world data predictors for conversion to progressive multiple sclerosis"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-3745","authenticated-orcid":false,"given":"Luis Rafael","family":"Sol\u00eds-Tarazona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Molina-Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Barea-Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Galan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7099-2314","authenticated-orcid":false,"given":"Lars Lau","family":"Raket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-0116","authenticated-orcid":false,"given":"Sara","family":"Gil-Perotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106674_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00280","article-title":"Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?","volume":"10","author":"Abdelhak","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106674_bib0003","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1172\/JCI86198","article-title":"Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions","volume":"126","author":"Absinta","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2025.106674_bib0004","article-title":"Serum neurofilament light chain: no clear relation to cognition and neuropsychiatric symptoms in stable MS","volume":"7","author":"Aktas","year":"2020","journal-title":"Neurol.(R) Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106674_bib0005","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1177\/13524585221114750","article-title":"Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis","volume":"28","author":"Altokhis","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106674_bib0006","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105747","article-title":"Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up","volume":"89","author":"Ayrignac","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106674_bib0008","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106674_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106674_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103115","article-title":"Early predictors of conversion to secondary progressive multiple sclerosis","volume":"54","author":"Barzegar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106674_bib0011","article-title":"Prevalence of elevated sNFL in a real-world setting: results on 908 patients with different multiple sclerosis types and treatment conditions","volume":"88","author":"Bava","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106674_bib0012","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the symbol digit Modalities Test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106674_bib0013","article-title":"Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B-cell depleting treatment in multiple sclerosis","author":"Benkert","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0014","article-title":"CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis","volume":"7","author":"Bhan","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106674_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200253","article-title":"Central vein sign, cortical lesions, and paramagnetic rim lesions for the diagnostic and prognostic workup of Multiple sclerosis","volume":"11","author":"Borrelli","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106674_bib0016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jneuroim.2016.01.013","article-title":"YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis","volume":"292","author":"Burman","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106674_bib0017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ane.12239","article-title":"Assessing tissue damage in multiple sclerosis: a biomarker approach","volume":"130","author":"Burman","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2025.106674_bib0018","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207768","article-title":"Association of spinal cord atrophy and brain paramagnetic rim lesions with progression independent of relapse activity in people with MS","volume":"102","author":"Cagol","year":"2024","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106674_bib0019","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","article-title":"Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years","volume":"76","author":"Cant\u00f3","year":"2019","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0020","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1177\/1352458516635874","article-title":"Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients","volume":"22","author":"Cavallari","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106674_bib0021","first-page":"1401","article-title":"The faces of \u201ctoo late\u201d\u2014A surprisingly progressive cohort of \u201cstable\u201d relapsing remitting multiple sclerosis patients","volume":"60","author":"Ciubotaru","year":"2024","journal-title":"Med. (B Aires)"},{"key":"10.1016\/j.msard.2025.106674_bib0022","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(12)70059-5","article-title":"Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects","volume":"11","author":"Cohen","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0023","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0024","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106674_bib0025","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/1352458520936214","article-title":"Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis","volume":"27","author":"Conway","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106674_bib0026","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2019.05.019","article-title":"Review: patient-reported outcomes in multiple sclerosis care","volume":"33","author":"D\u2019Amico","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106674_bib0027","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ensci.2018.07.002","article-title":"Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis","volume":"12","author":"Dastagir","year":"2018","journal-title":"eNeurologicalSci."},{"key":"10.1016\/j.msard.2025.106674_bib0028","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1177\/1352458519864933","article-title":"Infratentorial and spinal cord lesions: cumulative predictors of long-term disability?","volume":"26","author":"Dekker","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106674_bib0029","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The nine-hole peg Test as a manual dexterity performance measure for multiple sclerosis","volume":"23","author":"Feys","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106674_bib0031","doi-asserted-by":"crossref","unstructured":"Filli L, Hofstetter L, Kuster P, et al. Spatiotemporal distribution of white matter lesions in relapsing\u2013remitting and secondary progressive multiple sclerosis. 101177\/1352458512442756 2012; 18: 1577\u20131584.","DOI":"10.1177\/1352458512442756"},{"key":"10.1016\/j.msard.2025.106674_bib0032","unstructured":"Fox RJ, Bar-Or A, Traboulsee A, et al. Efficacy and safety of Tolebrutinib versus Placebo in non-relapsing secondary progressive multiple sclerosis: results from the phase 3 HERCULES trial on behalf of the Tolebrutinib Phase 3 HERCULES Trial Group."},{"key":"10.1016\/j.msard.2025.106674_bib0033","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/mrm.20792","article-title":"MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis","volume":"55","author":"Geurts","year":"2006","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.msard.2025.106674_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23088-x","article-title":"Patient\u2019s perspective in clinical practice to assess and predict disability in multiple sclerosis","volume":"12","author":"Gil-Perotin","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106674_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.01008","article-title":"Combined cerebrospinal fluid neurofilament light chain protein and chitinase-3 like-1 levels in defining disease course and prognosis in multiple sclerosis","volume":"10","author":"Gil-Perotin","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0036","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008519","article-title":"Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data","volume":"93","author":"Goldman","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106674_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14030237","article-title":"Morphosyntactic abilities and cognitive performance in multiple sclerosis","volume":"14","author":"Grigoriadis","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.msard.2025.106674_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123073","article-title":"Evaluation of the T25FW in minimally disabled people with multiple sclerosis","volume":"462","author":"Helmlinger","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106674_bib0039","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1177\/13524585221102921","article-title":"Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: a retrospective cross-sectional study","volume":"28","author":"Hemond","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106674_bib0040","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1177\/1352458514561906","article-title":"Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis","volume":"21","author":"Hinsinger","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106674_bib0041","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity","volume":"26","author":"H\u00f6gel","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106674_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00608","article-title":"A score based on NfL and glial markers may differentiate between relapsing\u2013remitting and progressive MS course","volume":"11","author":"Huss","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0043","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200279","article-title":"Neurofilament light chain serum levels mirror age and disability in secondary progressive Multiple sclerosis: a cross-sectional study","volume":"11","author":"Husseini","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106674_bib0044","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1179\/174313209X455664","article-title":"Rapid communication: neuropsychiatric manifestations in multiple sclerosis: correlation of fatigue and depression with disease progression","volume":"32","author":"Kale","year":"2010","journal-title":"Neurol. Res."},{"key":"10.1016\/j.msard.2025.106674_bib0045","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106674_bib0046","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/1352458515604905","article-title":"Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis","volume":"22","author":"Kearney","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106674_bib0047","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jnnp-2014-308241","article-title":"Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis","volume":"86","author":"Kearney","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106674_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-024-03036-4","article-title":"Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes","volume":"21","author":"Kodosaki","year":"2024","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.msard.2025.106674_bib0049","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106674_bib0050","first-page":"433","article-title":"Quality of life in multiple sclerosis - association with clinical features, fatigue and depressive syndrome","volume":"47","author":"Labuz-Roszak","year":"2013","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.msard.2025.106674_bib0051","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/jnnp-2023-331799","article-title":"Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis","volume":"95","author":"Lauerer","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106674_bib0052","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1177\/1352458510377905","article-title":"T2 hypointense rims and ring-enhancing lesions in MS","volume":"16","author":"Llufriu","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106674_bib0053","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12035-022-03060-6","article-title":"CSF CXCL13 and Chitinase 3-like-1 levels predict disease course in relapsing multiple sclerosis","volume":"60","author":"Lucchini","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.msard.2025.106674_bib0054","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10072-012-0974-4","article-title":"Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis","volume":"34","author":"Madeddu","year":"2013","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106674_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.52187","article-title":"Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis","author":"Madill","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0056","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-08477-6","article-title":"Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis","volume":"12","author":"Marcille","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106674_bib0057","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/1352458514549397","article-title":"Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis","volume":"21","author":"Mart\u00ednez","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106674_bib0058","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awae260","article-title":"Serum biomarkers at disease onset for personalized therapy in multiple sclerosis","author":"Monreal","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106674_bib0061","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1468-1331.2010.03093.x","article-title":"T2 lesions and rate of progression of disability in multiple sclerosis","volume":"17","author":"Mostert","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0062","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/1352458517690823","article-title":"Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis","volume":"23","author":"Motl","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106674_bib0063","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0064","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14171993","article-title":"Can selected parameters of brain injury reflect neuronal damage in smoldering multiple sclerosis?","volume":"14","author":"Niedziela","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.msard.2025.106674_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14111120","article-title":"Advanced MRI techniques: diagnosis and follow-up of multiple sclerosis","volume":"14","author":"Nistri","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.msard.2025.106674_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194828","article-title":"Searching for neurodegeneration in multiple sclerosis at clinical onset: diagnostic value of biomarkers","volume":"13","author":"Novakova","year":"2018","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2025.106674_bib0067","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1223220","article-title":"Predictive value of brain atrophy, serum biomarkers and information processing speed for early disease progression in multiple sclerosis","volume":"14","author":"Oset","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0069","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/awaa249","article-title":"7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis","volume":"143","author":"Ouellette","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106674_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.msard.2025.106674_bib0071","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2025.106674_bib0072","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/brain\/awf165","article-title":"Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations","volume":"125","author":"Petzold","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106674_bib0073","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1007\/s00330-022-09338-6","article-title":"Quantitative susceptibility mapping of the normal-appearing white matter as a potential new marker of disability progression in multiple sclerosis","volume":"33","author":"Pietroboni","year":"2023","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.msard.2025.106674_bib0074","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106674_bib0075","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.msard.2019.01.011","article-title":"Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis","volume":"28","author":"Rooney","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106674_bib0076","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1177\/13524585211039104","article-title":"Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study","volume":"28","author":"Rosenstein","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106674_bib0077","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ana.410400321","article-title":"Clinical outcomes assessment in multiple sclerosis","volume":"40","author":"Rudick","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0078","first-page":"5559","article-title":"Cognitive impairment in different clinical forms of multiple sclerosis","volume":"30","author":"Sadarzanska-Terzieva","year":"2024","journal-title":"J. IMAB - Annu. Proceeding (Sci. Pap.)"},{"key":"10.1016\/j.msard.2025.106674_bib0079","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/1352458520929192","article-title":"Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study","volume":"27","author":"Sechi","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106674_bib0080","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1177\/1352458518794308","article-title":"Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis","volume":"25","author":"Sellebjerg","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106674_bib0081","doi-asserted-by":"crossref","DOI":"10.1186\/s41983-023-00779-4","article-title":"Predictors of progression of multiple sclerosis in a sample of Egyptian patients","volume":"60","author":"Shawky","year":"2024","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"10.1016\/j.msard.2025.106674_bib0082","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2019.01.043","article-title":"Clinical correlates of 9-hole peg test in a large population of people with multiple sclerosis","volume":"30","author":"Solaro","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106674_bib0083","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1354431","article-title":"Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis","volume":"15","author":"Sol\u00eds-Tarazona","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0084","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200055","article-title":"Serum neurofilament identifies patients with multiple sclerosis with severe focal axonal damage in a 6-year longitudinal cohort","volume":"10","author":"Steffen","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106674_bib0085","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s10072-023-06764-2","article-title":"Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis","volume":"44","author":"Talaat","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106674_bib0086","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67504-6","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"Thebault","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106674_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103535","article-title":"High or increasing serum NfL is predictive of impending multiple sclerosis relapses","volume":"59","author":"Thebault","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106674_bib0088","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/ane.13554","article-title":"Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis","volume":"145","author":"Theodorsdottir","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2025.106674_bib0089","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13760-017-0828-1","article-title":"Long-term disability and progression in spinal onset multiple sclerosis","volume":"118","author":"Tiftikcioglu","year":"2018","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2025.106674_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103590","article-title":"NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: serum NfL predicts relapse-free progression","volume":"72","author":"Uphaus","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2025.106674_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103165","article-title":"The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis","volume":"55","author":"van \u2018t Hullenaar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106674_bib0092","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1007\/s00415-023-11676-4","article-title":"A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort","volume":"270","author":"van Dam","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2024.103593","article-title":"Comparative overview of multi-shell diffusion MRI models to characterize the microstructure of multiple sclerosis lesions and periplaques","volume":"42","author":"Vanden Bulcke","year":"2024","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.msard.2025.106674_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurad.2023.10.010","article-title":"Rim lesions in MS at 3T: clinical correlation and possible radiological alternatives for daily practice at lower field strength","volume":"51","author":"Vanheule","year":"2024","journal-title":"J. Neuroradiol."},{"key":"10.1016\/j.msard.2025.106674_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105412","article-title":"Serum and cerebrospinal fluid neurofilament light chains measured by SIMOATM, EllaTM, and LumipulseTM in multiple sclerosis na\u00efve patients","volume":"82","author":"Vecchio","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106674_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105412","article-title":"Serum and cerebrospinal fluid neurofilament light chains measured by SIMOATM, EllaTM, and LumipulseTM in multiple sclerosis na\u00efve patients","volume":"82","author":"Vecchio","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106674_bib0097","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106674_bib0098","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200045","article-title":"Effect of estimated blood volume and body mass index on GFAP and NfL levels in the serum and CSF of patients with multiple sclerosis","volume":"10","author":"Yalachkov","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106674_bib0099","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s11845-020-02377-2","article-title":"The relationship between cognition, depression, fatigue, and disability in patients with multiple sclerosis","volume":"190","author":"Yigit","year":"2021","journal-title":"Ir. J. Med. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500416X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500416X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:17:30Z","timestamp":1774999050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500416X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":99,"alternative-id":["S221103482500416X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106674","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of real-world data predictors for conversion to progressive multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106674"}}